keyword
MENU ▼
Read by QxMD icon Read
search

"peptide receptor radionuclide therapy"

keyword
https://www.readbyqxmd.com/read/29422353/editorial-peptide-receptor-radionuclide-therapy-as-neoadjuvant-therapy-for-resectable-or-potentially-resectable-pancreatic-neuroendocrine-neoplasms
#1
EDITORIAL
https://www.readbyqxmd.com/read/29399055/refractory-thyroid-carcinoma-which-systemic-treatment-to-use
#2
REVIEW
Laurence Faugeras, Anne-Sophie Pirson, Julian Donckier, Luc Michel, Julien Lemaire, Sebastien Vandervorst, Lionel D'Hondt
The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on the tumor subtype. Still, many of these cancers will recur and may be treated with radioactive iodine or another surgery. It is unclear what treatment is best for cases of locally advanced or metastatic thyroid cancer that are refractory to radioactive iodine. Chemotherapy has a very low response rate...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29398960/177lu-dotatate-peptide-receptor-radionuclide-therapy-in-patients-with-borderline-low-and-discordant-renal-parameters-treatment-feasibility-assessment-by-sequential-estimation-of-triple-parameters-and-filtration-fraction
#3
Chinna Naik, Sandip Basu
The aim was to assess the effect of standard fixed-dose protocol of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with borderline low renal function of one parameter (glomerular filtration rate [GFR], effective renal plasma flow [ERPF] or serum creatinine), that was discordant with the remaining parameters and determine the feasibility of this procedure in this group of patients. Renal toxicity of PRRT is a routine issue or concern for such cases. We compared different renal parameters used for pretherapy assessment in patients with borderline low single parameter at baseline and their potential significance with regards to deterioration of renal function subsequently...
January 2018: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29387927/investigation-of-receptor-radionuclide-therapy-with-177lu-dotatate-in-patients-with-gep-nen-and-a-high-ki-67-proliferation-index
#4
Silvia Nicolini, Stefano Severi, Annarita Ianniello, Maddalena Sansovini, Alice Ambrosetti, Alberto Bongiovanni, Emanuela Scarpi, Francesca Di Mauro, Alice Rossi, Federica Matteucci, Giovanni Paganelli
PURPOSE: In the 2010 WHO classification, a Ki-67 proliferation index of 20% is the cut-off between intermediate-grade and high-grade gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN). However, in clinical practice, tumours with a Ki-67 index of >15% are often considered high grade and treated with chemotherapy. In 40-70% of high-grade NENs, somatostatin receptors are overexpressed, enabling peptide receptor radionuclide therapy (PRRT) to be performed. We investigated the role of PRRT with 177Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index...
February 1, 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/29383428/from-initial-description-by-wermer-to-present-day-men1-what-have-we-learned
#5
Nancy D Perrier
INTRODUCTION: Pancreas, parathyroid, and pituitary, are referred to as the "3 Ps" of MEN1. The time has come to move beyond those Ps and begin to discuss (1) prediction, (2) pausing progression, and (3) prevention of MEN1. METHODS: In preparation for the International Association of Endocrine Surgeons State of the Art address, updates and uncertainties of MEN were reviewed. This included a detailed examination of the MEN1 gene and the library of implicated mutations, exon sequencing databases and cell cycle pathways...
January 30, 2018: World Journal of Surgery
https://www.readbyqxmd.com/read/29375864/apparent-pacemaker-dysfunction-during-peptide-receptor-radionuclide-therapy-for-neuroendocrine-tumor
#6
Stefan Asbach, Fabienne Schluermann, Juri Ruf, Christoph Bode, Corinna Lang
This case is a reminder not to overlook rare causes of electrolyte shifts, which may cause reversible changes in pacemaker pacing thresholds.
January 2018: Clinical Case Reports
https://www.readbyqxmd.com/read/29356741/tumor-cystic-necrosis-following-peptide-receptor-radionuclide-therapy-in-neuroendocrine-tumors
#7
Rahul Ladwa, Hooi Wen Hong, David Wyld, David A Pattison, Matthew Burge
The response assessment to peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors is complex. We present the case of a 49-year-old man with metastatic rectal neuroendocrine tumor whose clinical symptoms and response evaluation criteria in solid tumors suggested progressive disease following PRRT. However, Ga-DOTA-(Tyr3)-octreotate PET/CT showed a partial scintigraphic response with absence of F-FDG PET/CT uptake consistent with tumor cystic necrosis. Long-term follow-up confirmed ongoing tumor response to treatment...
January 19, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29344308/-albumin-hitchhiking-with-an-evans-blue-analog-for-cancer-theranostics
#8
EDITORIAL
Emily B Ehlerding, Xiaoli Lan, Weibo Cai
Although 177Lu-DOTA-TATE was recently approved in Europe for the treatment of certain neuroendocrine tumors, continued development and optimization has been ongoing to further improve the therapeutic efficacy of somatostatin receptor 2 targeted peptide receptor radionuclide therapy, as well as reducing the renal toxicity. In this work, the use of an Evans blue analog for "albumin hitchhiking" resulted in significant improvement in both the imaging performance and therapeutic efficacy of radiolabeled octreotate, as well as reducing the toxicity since much less radioactivity was used for therapy...
2018: Theranostics
https://www.readbyqxmd.com/read/29344295/peptide-receptor-radionuclide-therapy-as-a-new-tool-in-treatment-refractory-sarcoidosis-initial-experience-in-two-patients
#9
Constantin Lapa, Malte Kircher, Heribert Hänscheid, Andreas Schirbel, Götz Ulrich Grigoleit, Erdwine Klinker, Markus Böck, Samuel Samnick, Theo Pelzer, Andreas K Buck
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors. Methods: We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT...
2018: Theranostics
https://www.readbyqxmd.com/read/29315138/peptide-receptor-radionuclide-therapy-with-177lu-dota-octreotate-dosimetry-nephrotoxicity-and-the-effect-of-hematological-toxicity-on-survival
#10
Anastassia Löser, Sarah M Schwarzenböck, Martin Heuschkel, Holger S Willenberg, Bernd J Krause, Jens Kurth
OBJECTIVES: Peptide receptor radionuclide therapy (PRRT) with lutetium-177 (Lu)-DOTATATE is regarded as a safe treatment option with promising results for patients with neuroendocrine neoplasia (NEN). We aimed to study the absorbed organ and tumor doses, the renal and hematological toxicity as well as their mutual interaction. Another aim was the identification of adverse effects as possible predictors which may affect survival. METHODS: A total of 30 (14 female and 16 male) patients with inoperable/metastatic NEN were treated with 7...
January 8, 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29299370/safety-of-selective-internal-radiation-therapy-sirt-with-yttrium-90-microspheres-combined-with-systemic-anticancer-agents-expert-consensus
#11
REVIEW
Andrew Kennedy, Daniel B Brown, Jonas Feilchenfeldt, John Marshall, Harpreet Wasan, Marwan Fakih, Peter Gibbs, Alexander Knuth, Bruno Sangro, Michael C Soulen, Gianfranco Pittari, Ricky A Sharma
Selective internal radiation therapy (SIRT) with microspheres labelled with the β-emitter yttrium-90 (Y-90) enables targeted delivery of radiation to hepatic tumors. SIRT is primarily used to treat inoperable primary or metastatic liver tumors. Eligible patients have usually been exposed to a variety of systemic anticancer therapies, including cytotoxic agents, targeted biologics, immunotherapy and peptide receptor radionuclide therapy (PRRT). All these treatments have potential interactions with SIRT; however, robust evidence on the safety of these potential combinations is lacking...
December 2017: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/29284590/peptide-receptor-radionuclide-therapy-as-neoadjuvant-therapy-for-resectable-or-potentially-resectable-pancreatic-neuroendocrine-neoplasms
#12
Stefano Partelli, Emilio Bertani, Mirco Bartolomei, Carolina Perali, Francesca Muffatti, Chiara Maria Grana, Marco Schiavo Lena, Claudio Doglioni, Stefano Crippa, Nicola Fazio, Giuseppe Zamboni, Massimo Falconi
BACKGROUND: Peptide receptor radionuclide therapy is a valid therapeutic option for pancreatic neuroendocrine neoplasms. The aim of this study was to describe an initial experience with the use of peptide receptor radionuclide therapy as a neoadjuvant agent for resectable or potentially resectable pancreatic neuroendocrine neoplasms. METHODS: The postoperative outcomes of 23 patients with resectable or potentially resectable pancreatic neuroendocrine neoplasms at high risk of recurrence who underwent neoadjuvant peptide receptor radionuclide therapy (peptide receptor radionuclide therapy group) were compared with 23 patients who underwent upfront surgical operation (upfront surgery group)...
December 25, 2017: Surgery
https://www.readbyqxmd.com/read/29229497/advanced-neuroendocrine-tumours-of-the-small-intestine-and-pancreas-clinical-developments-controversies-and-future-strategies
#13
REVIEW
Christoph J Auernhammer, Christine Spitzweg, Martin K Angele, Stefan Boeck, Ashley Grossman, Svenja Nölting, Harun Ilhan, Thomas Knösel, Julia Mayerle, Martin Reincke, Peter Bartenstein
In this Review, we discuss clinical developments and controversies in the treatment of neuroendocrine tumours (NETs) that are relevant for clinicians and clinical researchers. We describe advances in genetics, blood-based biomarkers, functional imaging, and systemic therapy of advanced NETs and discuss results of recent phase 3 studies, systemic treatment of advanced disease with peptide receptor radionuclide therapy, biotherapy, chemotherapy, and molecularly targeted therapy, and the potential role of immunotherapy in the treatment of NETs...
December 8, 2017: Lancet Diabetes & Endocrinology
https://www.readbyqxmd.com/read/29206780/neoadjuvant-strategies-for-advanced-pancreatic-neuroendocrine-tumors-should-combined-chemotherapy-and-peptide-receptor-radionuclide-therapy-be-the-preferred-regimen-for-maximizing-outcome
#14
Sandip Basu, Rahul V Parghane, Vikas Ostwal, Shailesh V Shrikhande
No abstract text is available yet for this article.
January 2018: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/29205458/multi-disciplinary-management-of-refractory-insulinomas
#15
Emily Brown, Daniel Watkin, Jonathan Evans, Vincent Yip, Daniel J Cuthbertson
Insulinomas are predominantly benign (~90%), pancreatic neuroendocrine tumours characterised by hyperinsulinaemic hypoglycaemia. They usually present as a small (<2cm), well demarcated, solitary nodule that can arise in any part of the organ. Treatment of sporadic insulinomas is generally aimed at curative surgical resection with special consideration in genetic syndromes. Patients with significant hypoglycaemia can pose a difficult management challenge. In isolated cases where the patient is not medically fit for surgery or with metastatic spread, other treatment options are employed...
December 4, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/29201454/the-role-of-peptide-receptor-radionuclide-therapy-in-advanced-metastatic-thoracic-neuroendocrine-tumors
#16
REVIEW
Lisa Bodei, Jarosław B Ćwikla, Mark Kidd, Irvin M Modlin
Bronchopulmonary (BP) neuroendocrine tumors (NETs) comprise a spectrum of tumors that develop from respiratory neuroendocrine cells and represent ~20% of all lung neoplasia and ~30% of all NETs. The only curative treatment is surgical resection. For well-differentiated forms (typical and atypical carcinoids), medical therapy ranges from bioactive agents (e.g., somatostatin analogs), to biotherapy (e.g., everolimus), standard chemotherapy and peptide receptor radionuclide therapy (PRRT). PRRT with radiolabeled somatostatin analogs is an innovative treatment for inoperable or metastasized, well/moderately differentiated, NET...
November 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29201453/the-role-of-multimodal-treatment-in-patients-with-advanced-lung-neuroendocrine-tumors
#17
REVIEW
Nicola Fazio, Antonio Ungaro, Francesca Spada, Chiara Alessandra Cella, Eleonora Pisa, Massimo Barberis, Chiara Grana, Dario Zerini, Emilio Bertani, Dario Ribero, Luigi Funicelli, Guido Bonomo, Davide Ravizza, Juliana Guarize, Filippo De Marinis, Francesco Petrella, Ester Del Signore, Giuseppe Pelosi, Lorenzo Spaggiari
Lung neuroendocrine tumors (NETs) comprise typical (TC) and atypical carcinoids (AC). They represent the well differentiated (WD) or low/intermediate grade forms of lung neuroendocrine neoplasms (NENs). Unlike the lung poorly differentiated NENs, that are usually treated with chemotherapy, lung NETs can be managed with several different therapies, making a multidisciplinary interaction a key point. We critically discussed the multimodal clinical management of patients with advanced lung NETs. Provided that no therapeutic algorithm has been validate so far, each clinical case should be discussed within a NEN-dedicated multidisciplinary team...
November 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29188154/somatostatin-receptor-avidity-in-gastrointestinal-stromal-tumors-theranostic-implications-of-gallium-68-scan-and-eligibility-for-peptide-receptor-radionuclide-therapy
#18
Arturo Loaiza-Bonilla, Paula A Bonilla-Reyes
This manuscript reports on a patient with a metastatic gastrointestinal stromal tumor (GIST) refractory to standard first-line treatment, who underwent a gallium-68 scan based on pre-clinical data of somatostatin receptor (SSTR) expression in such tumors. The gallium-68 DOTATATE scan determined significant somatostatin receptor avidity as hypothesized, suggesting that this imaging modality may be used as an option for diagnostic and follow-up purposes in GIST patients. In addition, peptide receptor-mediated radiotherapy (177Lu-PPRT) via SSTR may provide a novel treatment strategy in carefully selected SSTR-avid GIST patients with thyrosine kinase inhibitor (TKI)-resistant tumors such as this case, and this warrants further investigation in novel clinical trial concepts...
September 24, 2017: Curēus
https://www.readbyqxmd.com/read/29177165/theranostics-of-neuroendocrine-tumors
#19
REVIEW
Sze Ting Lee, Harshad R Kulkarni, Aviral Singh, Richard P Baum
Somatostatin receptor positron emission tomography/computed tomography using 68Ga-labeled somatostatin analogs is the mainstay for the evaluation of receptor status in neuroendocrine tumors (NETs). This translates towards better therapy options, with increasing evidence of peptide receptor radionuclide therapy (PRRT) as the treatment of choice for advanced or progressive NETs. There are benefits in progression-free and overall survival as well as a significant improvement in clinical condition. In patients with progressive NETs, fractionated, personalized PRRT results in good therapeutic responses with no significant severe hematological and/or renal toxicity, thus improving quality of life...
October 2017: Visceral Medicine
https://www.readbyqxmd.com/read/29177164/medical-therapy-of-gastrointestinal-neuroendocrine-tumors
#20
REVIEW
Kjell Öberg
Intestinal neuroendocrine tumors (NETs) constitute a heterogeneous group with duodenal, small intestinal, colonic and rectal NETs. They constitute more than half of all NETs, with the highest frequencies in the rectum, small intestine, and colon. The tumor biology varies with the location of the primary tumor as well as with the grade and staging of the tumor. Small intestinal NETs usually present low proliferation and are treated in the first line with somatostatin analogs according to current guidelines. If progression occurs, one can add interferon alpha or change the treatment to everolimus...
October 2017: Visceral Medicine
keyword
keyword
108898
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"